Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Clinical trial NCT05063916 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05063916
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2027-08-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.